45 drugs in the first batch of low price purchase catalogue

Another indication of pajite, a Roche breast cancer innovative target drug, has been approved in China; the first PD-L1 in mainland China has been approved for listing; 45 drugs have entered the first batch of low-cost procurement catalogue; Qiming medical has been listed today; Btk inhibitors have become the focus of research and development Roche China today announced that China's State Drug Administration has officially approved the first-line standard treatment plan for patients with HER2 positive metastatic breast cancer who have not received anti HER2 treatment or chemotherapy, which is based on combination of pajiete (patozumab), Herceptin (trastuzumab) and docetaxel The approval of this program has realized the gradual internationalization of the treatment program for HER2 positive advanced breast cancer patients in China, will bring more long-term survival benefits for HER2 positive advanced breast cancer patients, help to realize the slow disease management of breast cancer diagnosis and treatment, and make it possible for advanced breast cancer to get rid of "terminal disease" On December 9, the State Drug Administration updated the processing status (acceptance No.: jxss1800040 / 41) of AstraZeneca PD-L1 monoclonal antibody imfinzi (durvalumab, duvalyiumab) and changed it to "approved - to be certified" Imfinzi has been approved for the treatment of unresectable stage III non-small cell lung cancer (NSCLC) which has not progressed after concurrent radiotherapy and chemotherapy This is the sixth immunocheckpoint preparation listed in China and the first PD-L1 monoclonal antibody listed in mainland China At this year's ash annual meeting, the research and development progress of BTK inhibitors is also one of the focuses of the industry Baiji Shenzhou, Lilai, AstraZeneca, and Janssen / Aberdeen have all published the latest clinical results of their Btk inhibitors Why do Btk inhibitors attract many large pharmaceutical companies for R & D? Where is the next step of R & D in this field? Click in to have a look On December 10, xinlitai released a notice that the company and its subsidiaries, xinlitai (Chengdu) biotechnology and xinlitai (Suzhou) pharmaceutical declared "recombinant all human anti PCSK9 monoclonal antibody injection", obtained the implied permission of clinical trials from the State Food and drug administration, and will carry out clinical trials in the near future Data shows that at present, only iloximab has been approved for import in China, and xinlitai is expected to become the pioneer of PCSK9 inhibitor in China On December 9, the joint procurement office of Wuhan pharmaceutical machinery issued the detailed rules for the implementation of the first batch of centralized drug volume procurement in Wuhan in 2019 and the first batch of centralized drug volume procurement catalogue in Wuhan in 2019, with 45 drugs released into the first batch of procurement catalogue : according to the published implementation rules, this catalogue is determined among the drugs purchased by the state and Hubei Province, and the range of the selected varieties is the drugs and class II psychotropic drugs that are online in the "Hubei provincial centralized purchasing service platform for medical devices" and have transaction volume in medical institutions in Wuhan area before June 30, 2019 On December 10, the star medical device enterprise was officially listed on the stock exchange of Hong Kong with the securities code of 02500.hk The IPO price is HK $33 / share, with a total of 78537500 shares issued The opening price is HK $39 / share, with a market value of HK $15.7 billion as of the issuance So far, Qiming medical has become the first unprofitable medical device enterprise listed according to the new Hong Kong stock standard It is reported that during the previous offering period, Qiming medical has obtained 312 times of over subscription, which is extremely hot On December 9, MSD and arqule jointly announced that they had reached an acquisition agreement MSD will acquire all the publicly issued shares of arqule at a price of $20 per share through its subsidiaries, with a total amount of about $2.7 billion Arqule is focused on the development of small molecule kinase inhibitors for cancer and other diseases, through which MSD will expand its tumor pipeline According to the New York Times, the U.S federal government recently launched a program called "ready, set, The prep program will provide free pre exposure prophylactics for 200000 people at high risk of HIV who do not receive Medicaid, the Department of Veterans' health management or any other federal health program - Gilead's truvada and descovy, while the federal government will pay Gilead about $200 per bottle : Alex Azar, the US Secretary of health and human services, said in a statement announcing the plan on Tuesday that the $200 per bottle was used to subsidize Gilead's spending on delivering donated drugs from the factory to patients through the pharmaceutical supply chain, which Gilead claims is spent on the pharmaceutical supply chain Recently, Hubei Provincial Food and Drug Administration issued the notice on regulating the supervision and management of business license of drug retail chain enterprises (Draft for comments) The notice clearly points out that: for newly established drug retail chain enterprises, there must be more than 10 subordinate Direct stores in the province that have been accepted and issued by the local municipal and County Market Supervision Bureau (administrative examination and approval Bureau) Do drugstores want to develop and expand chain enterprises? The number of stores should be at least 10 In addition, the daily inspection should also face a more stringent regulatory situation.